Cargando…
Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens
BACKGROUND: Routine clinical management of breast cancer (BC) currently depends on surrogate subtypes according to estrogen- (ER) and progesterone (PR) receptor, Ki-67, and HER2-status. However, there has been growing demand for reduced immunohistochemistry (IHC) turnaround times. The Xpert® Breast...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059293/ https://www.ncbi.nlm.nih.gov/pubmed/33879115 http://dx.doi.org/10.1186/s12885-021-08171-2 |
_version_ | 1783681172850606080 |
---|---|
author | Janeva, Slavica Parris, Toshima Z. Nasic, Salmir De Lara, Shahin Larsson, Karolina Audisio, Riccardo A. Bagge, Roger Olofsson Kovács, Anikó |
author_facet | Janeva, Slavica Parris, Toshima Z. Nasic, Salmir De Lara, Shahin Larsson, Karolina Audisio, Riccardo A. Bagge, Roger Olofsson Kovács, Anikó |
author_sort | Janeva, Slavica |
collection | PubMed |
description | BACKGROUND: Routine clinical management of breast cancer (BC) currently depends on surrogate subtypes according to estrogen- (ER) and progesterone (PR) receptor, Ki-67, and HER2-status. However, there has been growing demand for reduced immunohistochemistry (IHC) turnaround times. The Xpert® Breast Cancer STRAT4* Assay (STRAT4)*, a standardized test for ESR1/PGR/MKi67/ERBB2 mRNA biomarker assessment, takes less than 2 hours. Here, we compared the concordance between the STRAT4 and IHC/SISH, thereby evaluating the effect of method choice on surrogate subtype assessment and adjuvant treatment decisions. METHODS: In total, 100 formalin-fixed paraffin-embedded core needle biopsy (CNB) samples and matching surgical specimens for 98 patients with primary invasive BC were evaluated using the STRAT4 assay. The concordance between STRAT4 and IHC was calculated for individual markers for the CNB and surgical specimens. In addition, we investigated whether changes in surrogate BC subtyping based on the STRAT4 results would change adjuvant treatment recommendations. RESULTS: The overall percent agreement (OPA) between STRAT4 and IHC/SISH ranged between 76 and 99% for the different biomarkers. Concordance for all four biomarkers in the surgical specimens and CNBs was only 66 and 57%, respectively. In total, 74% of surgical specimens were concordant for subtype, regardless of the method used. IHC- and STRAT4-based subtyping for the surgical specimen were shown to be discordant for 25/98 patients and 18/25 patients would theoretically have been recommended a different adjuvant treatment, primarily receiving more chemotherapy and trastuzumab. CONCLUSIONS: A comparison of data from IHC/in situ hybridization and STRAT4 demonstrated that subsequent changes in surrogate subtyping for the surgical specimen may theoretically result in more adjuvant treatment given, primarily with chemotherapy and trastuzumab. |
format | Online Article Text |
id | pubmed-8059293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80592932021-04-21 Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens Janeva, Slavica Parris, Toshima Z. Nasic, Salmir De Lara, Shahin Larsson, Karolina Audisio, Riccardo A. Bagge, Roger Olofsson Kovács, Anikó BMC Cancer Research BACKGROUND: Routine clinical management of breast cancer (BC) currently depends on surrogate subtypes according to estrogen- (ER) and progesterone (PR) receptor, Ki-67, and HER2-status. However, there has been growing demand for reduced immunohistochemistry (IHC) turnaround times. The Xpert® Breast Cancer STRAT4* Assay (STRAT4)*, a standardized test for ESR1/PGR/MKi67/ERBB2 mRNA biomarker assessment, takes less than 2 hours. Here, we compared the concordance between the STRAT4 and IHC/SISH, thereby evaluating the effect of method choice on surrogate subtype assessment and adjuvant treatment decisions. METHODS: In total, 100 formalin-fixed paraffin-embedded core needle biopsy (CNB) samples and matching surgical specimens for 98 patients with primary invasive BC were evaluated using the STRAT4 assay. The concordance between STRAT4 and IHC was calculated for individual markers for the CNB and surgical specimens. In addition, we investigated whether changes in surrogate BC subtyping based on the STRAT4 results would change adjuvant treatment recommendations. RESULTS: The overall percent agreement (OPA) between STRAT4 and IHC/SISH ranged between 76 and 99% for the different biomarkers. Concordance for all four biomarkers in the surgical specimens and CNBs was only 66 and 57%, respectively. In total, 74% of surgical specimens were concordant for subtype, regardless of the method used. IHC- and STRAT4-based subtyping for the surgical specimen were shown to be discordant for 25/98 patients and 18/25 patients would theoretically have been recommended a different adjuvant treatment, primarily receiving more chemotherapy and trastuzumab. CONCLUSIONS: A comparison of data from IHC/in situ hybridization and STRAT4 demonstrated that subsequent changes in surrogate subtyping for the surgical specimen may theoretically result in more adjuvant treatment given, primarily with chemotherapy and trastuzumab. BioMed Central 2021-04-21 /pmc/articles/PMC8059293/ /pubmed/33879115 http://dx.doi.org/10.1186/s12885-021-08171-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Janeva, Slavica Parris, Toshima Z. Nasic, Salmir De Lara, Shahin Larsson, Karolina Audisio, Riccardo A. Bagge, Roger Olofsson Kovács, Anikó Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title | Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title_full | Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title_fullStr | Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title_full_unstemmed | Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title_short | Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
title_sort | comparison of breast cancer surrogate subtyping using a closed-system rt-qpcr breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059293/ https://www.ncbi.nlm.nih.gov/pubmed/33879115 http://dx.doi.org/10.1186/s12885-021-08171-2 |
work_keys_str_mv | AT janevaslavica comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT parristoshimaz comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT nasicsalmir comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT delarashahin comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT larssonkarolina comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT audisioriccardoa comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT baggerogerolofsson comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens AT kovacsaniko comparisonofbreastcancersurrogatesubtypingusingaclosedsystemrtqpcrbreastcancerassayandimmunohistochemistryon100coreneedlebiopsieswithmatchingsurgicalspecimens |